You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Displaying Drugs List

9 Items
Other Name(s): Somatuline® Autogel® (Ipsen Biopharm Limited)
Funding:
ODB - General Benefit
  • lanreotide
Jan 2018
Other Name(s): Tykerb® (Novartis)
Funding:
Exceptional Access Program
  • lapatinib - Second-Line treatment of HER2 positive metastatic breast cancer in combination with chemotherapy after previous exposure to trastuzumab based treatments, with specific criteria
  • lapatinib - Treatment of HER-2 positive metastatic breast cancer when used in combination with chemotherapy after use of trastuzumab in patients who have an adverse drug reaction or contraindication to trastuzumab therapy
Jan 2018
Other Name(s): Revlimid® (Celgene)
Funding:
Exceptional Access Program
  • lenalidomide - Anemia due to MDS, with specific criteria
  • lenalidomide - For the maintenance treatment of patients with newly diagnosed multiple myeloma, following autologous stem-cell transplantation, according to specific criteria.
  • lenalidomide - Treatment of multiple myeloma in combination with dexamethasone, with specific criteria
May 2017
Other Name(s): Lenvima (Eisai)
Funding:
Exceptional Access Program
  • For the treatment of patients with locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer (DTC) according to criteria
Oct 2017
Other Name(s): Femara® (multiple brands available)
Funding:
ODB Limited Use
  • letrozole - Treatment of metastatic breast cancer in hormone receptor positive postmenopausal women
  • letrozole - As an alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer for a maximum of five years
  • letrozole - Treatment of hormone receptor positive early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy
Sep 2017
Other Name(s): Lederle Leucovorin® (multiple brands available)
Funding:
ODB - General Benefit
  • leucovorin - oral tablets
Dec 2017
Other Name(s): Lupron® (AbbVie); Lupron Depot® (AbbVie); Eligard® (Sanofi Aventis)
Funding:
ODB - General Benefit
  • leuprolide - long-acting formulation
Aug 2016
Other Name(s): Onivyde® (Baxalta Canada)
Sep 2017
Other Name(s): CeeNU® (Bristol-Myers Squibb)
Funding:
ODB - General Benefit
  • lomustine
Aug 2016